PBP 2a mutations producing very-high-level resistance to beta-lactams

被引:55
作者
Katayama, Y [1 ]
Zhang, HZ [1 ]
Chambers, HF [1 ]
机构
[1] Univ Calif San Francisco, SFGH, Div Infect Dis, Infect Dis Lab, San Francisco, CA 94143 USA
关键词
D O I
10.1128/AAC.48.2.453-459.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Resistance to the beta-lactam class of antibiotics in methicillin-resistant Staphylococcus aureus (MRSA) is mediated by PBP 2a, a synthetic bacterial cell wall penicillin-binding protein with a low affinity of binding to beta-lactams that is encoded by mecA. Beta-lactams that bind to PBP 2a with a high affinity and that are highly active against MRSA are under development. The potential for the emergence of resistance to such compounds was investigated by passage of homogeneous MRSA strain COL in L-695,256, an investigational carbapenem. A highly resistant mutant, COL52, expressed PBP 2a in which a two-amino-acid deletion mutation and three single-amino-acid substitution mutations were present. To examine the effects of these mutations on the resistance phenotype and PBP 2a production, plasmids carrying (i) PBP 2a with two or three of the four mutations, (ii) wild-type PBP 2a, or (iii) COL52 PBP 2a were introduced into methicillin-susceptible COL variants COLnex and COL52ex, from which the staphylococcus cassette chromosome mec (SCCmec) has been excised, as indicated by the "ex" suffix. Two amino acids substitutions, E --> K-237 within the non-penicillin-binding domain and V --> E-470 near the SDN464 conserved penicillin-binding motif in the penicillin-binding domain in COL52, were important for high-level resistance. The highest level of resistance was observed when all four mutations were present. The emergence of PBP 2a-mediated resistance to beta-lactams that bind to PBP 2a with a high affinity is likely to require multiple mutations in mecA; chromosomal mutations appear to have a minor role.
引用
收藏
页码:453 / 459
页数:7
相关论文
共 24 条
[1]  
[Anonymous], [No title captured]
[2]  
BERGERBACHI B, 1983, FEMS MICROBIOL LETT, V20, P305
[3]   Solving staphylococcal resistance to β-lactams [J].
Chambers, HF .
TRENDS IN MICROBIOLOGY, 2003, 11 (04) :145-148
[4]   IN NITRO AND IN-VIVO ANTISTAPHYLOCOCCAL ACTIVITIES OF L-695,256, A CARBAPENEM WITH HIGH-AFFINITY FOR THE PENICILLIN-BINDING PROTEIN PBP 2A [J].
CHAMBERS, HF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (02) :462-466
[5]   ENDOCARDITIS DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS IN RABBITS - EXPRESSION OF RESISTANCE TO BETA-LACTAM ANTIBIOTICS INVIVO AND INVITRO [J].
CHAMBERS, HF ;
HACKBARTH, CJ ;
DRAKE, TA ;
RUSNAK, MG ;
SANDE, MA .
JOURNAL OF INFECTIOUS DISEASES, 1984, 149 (06) :894-903
[6]   BINDING-AFFINITY FOR PENICILLIN-BINDING PROTEIN-2A CORRELATES WITH INVIVO ACTIVITY OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS [J].
CHAMBERS, HF ;
SACHDEVA, M ;
KENNEDY, S .
JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (03) :705-710
[7]   BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis [J].
Entenza, JM ;
Hohl, P ;
Heinze-Krauss, I ;
Glauser, MP ;
Moreillon, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :171-177
[8]   In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against methicillin-resistant and -susceptible staphylococci [J].
Fung-Tomc, JC ;
Clark, J ;
Minassian, B ;
Pucci, M ;
Tsai, YH ;
Gradelski, E ;
Lamb, L ;
Medina, I ;
Huczko, E ;
Kolek, B ;
Chaniewski, S ;
Ferraro, C ;
Washo, T ;
Bonner, DP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) :971-976
[9]   COMPARISON OF CONVENTIONAL SUSCEPTIBILITY TESTS WITH DIRECT DETECTION OF PENICILLIN-BINDING PROTEIN-2A IN BORDERLINE OXACILLIN-RESISTANT STRAINS OF STAPHYLOCOCCUS-AUREUS [J].
GERBERDING, JL ;
MIICK, C ;
LIU, HH ;
CHAMBERS, HF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (12) :2574-2579
[10]  
Ghuysen Jean-Marie, 1994, Trends in Microbiology, V2, P372, DOI 10.1016/0966-842X(94)90614-9